Reduction of the disintegrin and metalloprotease ADAM12 in preeclampsia.

Jennie Laigaard; Tina Sørensen; Sophie Placing; Peter Holck; Camilla Frohlich; Karen R Wøjdemann; Karin Sundberg; Anne-Cathrine Shalmi; Ann Tabor; Bent Nørgaard-Pedersen; Bent Ottesen; Michael Christiansen; Ulla M Wewer

doi:10.1097/01.AOG.0000165829.65319.65

Reduction of the disintegrin and metalloprotease ADAM12 in preeclampsia.

Jennie Laigaard, Tina Sørensen, Sophie Placing, Peter Holck, Camilla Frohlich, Karen R Wøjdemann, Karin Sundberg, Anne-Cathrine Shalmi, Ann Tabor, Bent Nørgaard-Pedersen, Bent Ottesen, Michael Christiansen, Ulla M Wewer

Department of Biomedical Sciences

99 Citations (Scopus)

Abstract

OBJECTIVES: The secreted form of ADAM12 is a metalloprotease that may be involved in placental and fetal growth. We examined whether the concentration of ADAM12 in first-trimester maternal serum could be used as a marker for preeclampsia. METHODS: We developed a semiautomated, time-resolved, immunofluorometric assay for the quantification of ADAM12 in serum. The assay detected ADAM12 in a range of 78-1248 microg/L. Serum samples derived from women in the first trimester of a normal pregnancy (n = 324) and from women who later developed preeclampsia during pregnancy (n = 160) were obtained from the First Trimester Copenhagen Study. ADAM12 levels were assayed in these serum samples. Serum levels of ADAM12 were converted to multiples of the median (MoM) after log-linear regression of concentration versus gestational age. RESULTS: Serum ADAM12 levels in women who developed preeclampsia during pregnancy had a mean log MoM of -0.066, which was significantly lower than the mean log MoM of -0.001 for ADAM12 levels observed in serum samples from women with normal pregnancy (P = .008). The mean log MoM was even lower in serum derived from preeclamptic women whose infant's weight at birth was less than 2,500 g (n = 27, mean log MoM of -0.120, P = .053). CONCLUSION: The maternal serum levels of ADAM12 are significantly lower during the first trimester in women who later develop preeclampsia during pregnancy when compared with levels in women with normal pregnancies. Because the secreted form of ADAM12 cleaves insulin-like growth factor binding protein (IGFBP)-3 and IGFBP-5, the IGF axis may play a role in preeclampsia. ADAM12 may be a useful early marker for preeclampsia. LEVEL OF EVIDENCE: II-2.

Original language	English
Journal	Obstetrics and Gynecology
Volume	106
Issue number	1
Pages (from-to)	144-9
Number of pages	5
ISSN	0029-7844
DOIs	https://doi.org/10.1097/01.AOG.0000165829.65319.65
Publication status	Published - 2005

Access to Document

10.1097/01.AOG.0000165829.65319.65

Cite this

@article{6b984ff05e3311dd8d9f000ea68e967b,

title = "Reduction of the disintegrin and metalloprotease ADAM12 in preeclampsia.",

abstract = "OBJECTIVES: The secreted form of ADAM12 is a metalloprotease that may be involved in placental and fetal growth. We examined whether the concentration of ADAM12 in first-trimester maternal serum could be used as a marker for preeclampsia. METHODS: We developed a semiautomated, time-resolved, immunofluorometric assay for the quantification of ADAM12 in serum. The assay detected ADAM12 in a range of 78-1248 microg/L. Serum samples derived from women in the first trimester of a normal pregnancy (n = 324) and from women who later developed preeclampsia during pregnancy (n = 160) were obtained from the First Trimester Copenhagen Study. ADAM12 levels were assayed in these serum samples. Serum levels of ADAM12 were converted to multiples of the median (MoM) after log-linear regression of concentration versus gestational age. RESULTS: Serum ADAM12 levels in women who developed preeclampsia during pregnancy had a mean log MoM of -0.066, which was significantly lower than the mean log MoM of -0.001 for ADAM12 levels observed in serum samples from women with normal pregnancy (P = .008). The mean log MoM was even lower in serum derived from preeclamptic women whose infant's weight at birth was less than 2,500 g (n = 27, mean log MoM of -0.120, P = .053). CONCLUSION: The maternal serum levels of ADAM12 are significantly lower during the first trimester in women who later develop preeclampsia during pregnancy when compared with levels in women with normal pregnancies. Because the secreted form of ADAM12 cleaves insulin-like growth factor binding protein (IGFBP)-3 and IGFBP-5, the IGF axis may play a role in preeclampsia. ADAM12 may be a useful early marker for preeclampsia. LEVEL OF EVIDENCE: II-2.",

author = "Jennie Laigaard and Tina S{\o}rensen and Sophie Placing and Peter Holck and Camilla Frohlich and W{\o}jdemann, {Karen R} and Karin Sundberg and Anne-Cathrine Shalmi and Ann Tabor and Bent N{\o}rgaard-Pedersen and Bent Ottesen and Michael Christiansen and Wewer, {Ulla M}",

note = "Keywords: Adult; Biological Markers; Case-Control Studies; Disintegrins; Female; Fluorescent Antibody Technique; Humans; Metalloproteases; Pre-Eclampsia; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Probability; Reference Values; Risk Factors; Sampling Studies; Sensitivity and Specificity",

year = "2005",

doi = "10.1097/01.AOG.0000165829.65319.65",

language = "English",

volume = "106",

pages = "144--9",

journal = "Obstetrics and Gynecology",

issn = "0029-7844",

publisher = "Lippincott Williams & Wilkins",

number = "1",

}

TY - JOUR

T1 - Reduction of the disintegrin and metalloprotease ADAM12 in preeclampsia.

AU - Laigaard, Jennie

AU - Sørensen, Tina

AU - Placing, Sophie

AU - Holck, Peter

AU - Frohlich, Camilla

AU - Wøjdemann, Karen R

AU - Sundberg, Karin

AU - Shalmi, Anne-Cathrine

AU - Tabor, Ann

AU - Nørgaard-Pedersen, Bent

AU - Ottesen, Bent

AU - Christiansen, Michael

AU - Wewer, Ulla M

N1 - Keywords: Adult; Biological Markers; Case-Control Studies; Disintegrins; Female; Fluorescent Antibody Technique; Humans; Metalloproteases; Pre-Eclampsia; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Probability; Reference Values; Risk Factors; Sampling Studies; Sensitivity and Specificity

PY - 2005

Y1 - 2005

N2 - OBJECTIVES: The secreted form of ADAM12 is a metalloprotease that may be involved in placental and fetal growth. We examined whether the concentration of ADAM12 in first-trimester maternal serum could be used as a marker for preeclampsia. METHODS: We developed a semiautomated, time-resolved, immunofluorometric assay for the quantification of ADAM12 in serum. The assay detected ADAM12 in a range of 78-1248 microg/L. Serum samples derived from women in the first trimester of a normal pregnancy (n = 324) and from women who later developed preeclampsia during pregnancy (n = 160) were obtained from the First Trimester Copenhagen Study. ADAM12 levels were assayed in these serum samples. Serum levels of ADAM12 were converted to multiples of the median (MoM) after log-linear regression of concentration versus gestational age. RESULTS: Serum ADAM12 levels in women who developed preeclampsia during pregnancy had a mean log MoM of -0.066, which was significantly lower than the mean log MoM of -0.001 for ADAM12 levels observed in serum samples from women with normal pregnancy (P = .008). The mean log MoM was even lower in serum derived from preeclamptic women whose infant's weight at birth was less than 2,500 g (n = 27, mean log MoM of -0.120, P = .053). CONCLUSION: The maternal serum levels of ADAM12 are significantly lower during the first trimester in women who later develop preeclampsia during pregnancy when compared with levels in women with normal pregnancies. Because the secreted form of ADAM12 cleaves insulin-like growth factor binding protein (IGFBP)-3 and IGFBP-5, the IGF axis may play a role in preeclampsia. ADAM12 may be a useful early marker for preeclampsia. LEVEL OF EVIDENCE: II-2.

AB - OBJECTIVES: The secreted form of ADAM12 is a metalloprotease that may be involved in placental and fetal growth. We examined whether the concentration of ADAM12 in first-trimester maternal serum could be used as a marker for preeclampsia. METHODS: We developed a semiautomated, time-resolved, immunofluorometric assay for the quantification of ADAM12 in serum. The assay detected ADAM12 in a range of 78-1248 microg/L. Serum samples derived from women in the first trimester of a normal pregnancy (n = 324) and from women who later developed preeclampsia during pregnancy (n = 160) were obtained from the First Trimester Copenhagen Study. ADAM12 levels were assayed in these serum samples. Serum levels of ADAM12 were converted to multiples of the median (MoM) after log-linear regression of concentration versus gestational age. RESULTS: Serum ADAM12 levels in women who developed preeclampsia during pregnancy had a mean log MoM of -0.066, which was significantly lower than the mean log MoM of -0.001 for ADAM12 levels observed in serum samples from women with normal pregnancy (P = .008). The mean log MoM was even lower in serum derived from preeclamptic women whose infant's weight at birth was less than 2,500 g (n = 27, mean log MoM of -0.120, P = .053). CONCLUSION: The maternal serum levels of ADAM12 are significantly lower during the first trimester in women who later develop preeclampsia during pregnancy when compared with levels in women with normal pregnancies. Because the secreted form of ADAM12 cleaves insulin-like growth factor binding protein (IGFBP)-3 and IGFBP-5, the IGF axis may play a role in preeclampsia. ADAM12 may be a useful early marker for preeclampsia. LEVEL OF EVIDENCE: II-2.

U2 - 10.1097/01.AOG.0000165829.65319.65

DO - 10.1097/01.AOG.0000165829.65319.65

M3 - Journal article

C2 - 15994630

SN - 0029-7844

VL - 106

SP - 144

EP - 149

JO - Obstetrics and Gynecology

JF - Obstetrics and Gynecology

IS - 1

ER -

Reduction of the disintegrin and metalloprotease ADAM12 in preeclampsia.

Abstract

Access to Document

Fingerprint

Cite this